In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 351 to 360 of 382

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]	Technology appraisal guidance	TBC
Topical tapinarof for treating atopic dermatitis in people 2 years and over ID6713	Technology appraisal guidance	TBC
Topical tapinarof for treating mild to severe plaque psoriasis ID6712	Technology appraisal guidance	TBC
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6406]	Technology appraisal guidance	2 December 2026
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over [ID6557]	Technology appraisal guidance	TBC
Transvaginal radiofrequency ablation for symptomatic uterine fibroids	HealthTech guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive advanced gastric or gastro-oesophageal junction adenocarcinoma after trastuzumab-based treatment (review of TA879) [ID6680]	Technology appraisal guidance	13 January 2027
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]	Technology appraisal guidance	TBC
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309]	Technology appraisal guidance	TBC
Trilaciclib for preventing myelosuppression caused by chemotherapy for extensive-stage small-cell lung cancer [ID6651]	Technology appraisal guidance	TBC

Results per page

10
25
50
All